Login to Your Account



Other News to Note


Wednesday, December 18, 2013

Qrxpharma Ltd., of Sydney, said the FDA established May 25, 2014, as the new Prescription Drug User Fee Act date for action on the company’s refiled new drug application for immediate-release Moxduo, a version of hydrocodone and morphine. The FDA will schedule an advisory committee meeting prior to that date, and assuming approval, the company said it plans to launch the product in the U.S. in the second half of 2014.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription